These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 22366594)
1. A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Dizon DS; Blessing JA; Penson RT; Drake RD; Walker JL; Johnston CM; Disilvestro PA; Fader AN Gynecol Oncol; 2012 May; 125(2):367-71. PubMed ID: 22366594 [TBL] [Abstract][Full Text] [Related]
2. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer. Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701 [TBL] [Abstract][Full Text] [Related]
3. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190 [TBL] [Abstract][Full Text] [Related]
4. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer. Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764 [TBL] [Abstract][Full Text] [Related]
5. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510 [TBL] [Abstract][Full Text] [Related]
6. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. Strauss HG; Henze A; Teichmann A; Karbe I; Baumgart A; Thomssen C; Koelbl H Gynecol Oncol; 2007 Mar; 104(3):612-6. PubMed ID: 17069876 [TBL] [Abstract][Full Text] [Related]
7. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473 [TBL] [Abstract][Full Text] [Related]
8. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Schmeler KM; Vadhan-Raj S; Ramirez PT; Apte SM; Cohen L; Bassett RL; Iyer RB; Wolf JK; Levenback CL; Gershenson DM; Freedman RS Gynecol Oncol; 2009 May; 113(2):210-5. PubMed ID: 19264351 [TBL] [Abstract][Full Text] [Related]
9. Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer. Dizon DS; Damstrup L; Finkler NJ; Lassen U; Celano P; Glasspool R; Crowley E; Lichenstein HS; Knoblach P; Penson RT Int J Gynecol Cancer; 2012 Jul; 22(6):979-86. PubMed ID: 22694911 [TBL] [Abstract][Full Text] [Related]
10. Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer. Schwandt A; von Gruenigen VE; Wenham RM; Frasure H; Eaton S; Fusco N; Fu P; Wright JJ; Dowlati A; Waggoner S Invest New Drugs; 2014 Aug; 32(4):729-38. PubMed ID: 24619298 [TBL] [Abstract][Full Text] [Related]
11. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330 [TBL] [Abstract][Full Text] [Related]
12. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. Landrum LM; Brady WE; Armstrong DK; Moore KN; DiSilvestro PA; O'Malley DM; Tenney ME; Rose PG; Fracasso PM Gynecol Oncol; 2016 Feb; 140(2):204-9. PubMed ID: 26616225 [TBL] [Abstract][Full Text] [Related]
13. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Del Carmen MG; Supko JG; Horick NK; Rauh-Hain JA; Clark RM; Campos SM; Krasner CN; Atkinson T; Birrer MJ Cancer; 2016 Nov; 122(21):3297-3306. PubMed ID: 27421044 [TBL] [Abstract][Full Text] [Related]
14. A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer. Sehouli J; Alvarez AM; Manouchehrpour S; Ghatage P; Szczylik C; Zimmermann A; Bauknecht T; Look KY; Oskay-Öezcelik G Gynecol Oncol; 2012 Feb; 124(2):205-9. PubMed ID: 22044606 [TBL] [Abstract][Full Text] [Related]
15. Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. Richardson DL; Moore KN; Vergote I; Gilbert L; Martin LP; Mantia-Smaldone GM; Castro CM; Provencher D; Matulonis UA; Stec J; Wang Y; Method M; O'Malley DM Gynecol Oncol; 2024 Jun; 185():186-193. PubMed ID: 38447347 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer. Hagemann AR; Novetsky AP; Zighelboim I; Gao F; Massad LS; Thaker PH; Powell MA; Mutch DG; Wright JD Gynecol Oncol; 2013 Dec; 131(3):535-40. PubMed ID: 24096113 [TBL] [Abstract][Full Text] [Related]
17. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma. Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691 [TBL] [Abstract][Full Text] [Related]
19. Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Matulonis U; Berlin S; Lee H; Whalen C; Obermayer E; Penson R; Liu J; Campos S; Krasner C; Horowitz N Cancer Chemother Pharmacol; 2015 Aug; 76(2):417-23. PubMed ID: 26119093 [TBL] [Abstract][Full Text] [Related]
20. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients. Safra T; Asna N; Veizman A; Shpigel S; Matcejevsky D; Inbar M; Grisaru D Anticancer Drugs; 2014 Mar; 25(3):340-5. PubMed ID: 24185383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]